The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).
Brigitte C. Widemann
No relevant relationships to disclose
Leigh Jessica Marcus
No relevant relationships to disclose
Michael J. Fisher
No relevant relationships to disclose
Brian D. Weiss
No relevant relationships to disclose
AeRang Kim
No relevant relationships to disclose
Eva Dombi
No relevant relationships to disclose
Andrea Baldwin
No relevant relationships to disclose
Patricia Whitcomb
No relevant relationships to disclose
Staci Martin
No relevant relationships to disclose
Andrea Gillespie
No relevant relationships to disclose
Austin Doyle
No relevant relationships to disclose